NCT07689591Recruiting
Noninvasive Artificial Venous Stasis for Reperfusion in STEMI
Noninvasive Artificial Venous Stasis and Coronary Reperfusion in ST-Segment Elevation Myocardial Infarction:The RE-START STEMI Randomized Trial
Source: ClinicalTrials.gov · Last updated 18 Aug 2026
Brief summary (registry, in English)
This prospective, randomized study was designed to evaluate whether the noninvasive artificial venous stasis / RE-START procedure, administered prior to primary percutaneous coronary intervention, increases the frequency of spontaneous coronary reperfusion in the infarct-related artery.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 30 Jun 2026
- Start date
- 15 Aug 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Firat University
- Diseases
- Coronary artery disease
- NCT number
- NCT07689591
What you commit to
- Study type: Observational
- Planned participants: 500
- From 15 Aug 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence of cardiogenic shock (systolic blood pressure \< 90 mmHg and Killip Class III-IV)
- Cardiac arrest occurring before or after the procedure
- Need for resuscitation following failed thrombolysis
- History of prior coronary artery bypass surgery
- Concurrent acute aortic dissection
- Venous thromboembolism or pulmonary embolism
- History of an acute infection within the past 7 days
- Chronic kidney disease requiring erythropoietin therapy or currently undergoing hemodialysis
- Presence of liver failure or a hematologic disorder
- Presence of any chronic inflammatory or autoimmune disease
- History of any known malignancy (cancer)
- Current treatment with glibenclamide, corticosteroids, antioxidant vitamins, or cyclosporine at the time of enrollment
- History of chronic (daily) alcohol consumption
- Contraindications to aspirin and/or clopidogrel
- Failure to confirm a STEMI diagnosis via coronary angiography
- Inability to provide informed consent
- Pregnancy
- First 6 months postpartum Conditions in which the administration of thrombolytics is contraindicated
Who the study is looking for
- Having presented within the first 12 hours of symptom onset Being hemodynamically stable (Killip Class I-II)
- STEMI diagnosis confirmed by coronary angiography
- Primary PCI (percutaneous coronary intervention) scheduled
- No pathology in the upper extremity that would prevent cuff application
- Be capable of providing informed consent and provide consent
Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Firat University Coordinator of this site? Confirm its status | Elâzığ | Turkey (Türkiye) | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.